Streetbeat News

Earnings

SLRN

Acelyrin Inc (NASDAQ:SLRN) released positive Phase 1/2 trial data for lonigutamab in thyroid eye disease, showing rapid improvements in symptoms with no serious adverse events. A Phase 2b/3 trial is planned for the second half of 2024. SLRN shares rose 6.53% to $8.48.

Portfolio Pulse from Vandana Singh

March 20, 2024 | 4:34 pm

TIGR

UP Fintech Holding Limited (NASDAQ:TIGR) reported its fourth-quarter FY23 results, showing a mixed financial performance. Total revenues increased by 9.6% year-over-year to $70.0 million, but total net revenues decreased by 4.7% to $54.0 million. The company saw a decline in commissions by 11.9% due to decreased trading volume, but interest income rose by 31.3% on higher margin financing and securities lending activities. UP Fintech added 39,034 new funded accounts, a 42.8% increase year-over-year, and the total account balance rose by 118.5% to $30.6 billion. However, non-GAAP net income per ADS was $0.007, missing the consensus of $0.07. The company also announced the introduction of the Combo Option Strategy feature and an upgrade to its Type 1 License by the Hong Kong SFC, allowing it to offer Virtual Asset dealing services to Professional Investors. Despite these developments, TIGR shares are down by 10.1% at $4.02.

Portfolio Pulse from Lekha Gupta

March 20, 2024 | 4:10 pm

BBY

Best Buy Co Inc (NYSE:BBY) reported higher-than-expected Q4 results, leading to an upgrade from Market Perform to Outperform by Telsey Advisory Group's Joseph Feldman, with a price target increase from $85 to $95. The upgrade is based on signs of stabilization and improvement in the business after nine quarters of negative comps. The company is expected to benefit from the start of a replacement cycle for products bought between 2019 and 2020, innovation in products like Samsung's AI-enabled phone and Microsoft’s Copilot laptops, and growth in higher margin services.

Portfolio Pulse from Priya Nigam

March 20, 2024 | 4:09 pm

HQI

HireQuest (NASDAQ:HQI) is scheduled to release its quarterly earnings report on Thursday, 2024-03-21, with analysts expecting an EPS of $-0.06. The company's past earnings performance shows a pattern of not meeting EPS estimates, leading to significant share price drops. Shares are currently trading at $12.08, down 41.15% over the last 52 weeks. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 4:02 pm

IDN

Intellicheck (NASDAQ:IDN) is scheduled to release its quarterly earnings report on Thursday, 2024-03-21, with analysts estimating an EPS of $0.00. The company's past earnings performance shows a pattern of not meeting EPS estimates, leading to significant share price movements. Shares of Intellicheck were trading at $1.77 as of March 19, reflecting a 27.6% decrease over the last 52-week period. Investors are likely focused on both the reported earnings and the company's future guidance.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 4:02 pm

XFOR

X4 Pharmaceuticals (NASDAQ:XFOR) is scheduled to release its quarterly earnings report on Thursday, 2024-03-21, with an expected EPS of $-0.15. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historically, X4 Pharmaceuticals has had mixed results in beating EPS estimates, with share price reactions varying accordingly. The stock has seen a 10.12% increase over the last 52 weeks, trading at $0.9708 as of March 19.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 4:01 pm

INKT

MiNK Therapeutics (NASDAQ:INKT) is scheduled to release its quarterly earnings report on March 21, 2024, with analysts expecting an EPS of $-0.15. The company's past earnings performance shows a mixed impact on its stock price, with the last quarter's beat leading to a 5.41% drop. Shares are currently trading at $0.86, marking a 59.7% decrease over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 4:01 pm

HYPR

Hyperfine (NASDAQ:HYPR) is scheduled to release its quarterly earnings report on March 21, 2024, with an estimated EPS of $-0.18. Investors are hopeful for a beat on this estimate and positive guidance for the next quarter. Historical data shows mixed reactions to past earnings, with the last quarter's beat followed by a 21.37% drop in share price. Shares are currently trading at $1.18, down 3.23% over the last year.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 4:01 pm

DXLG

Destination XL Group (NASDAQ:DXLG) is scheduled to release its quarterly earnings report on March 21, 2024, with analysts estimating an EPS of $0.06. The company's past earnings performance shows mixed results, with the last quarter missing EPS estimates by $0.00, leading to a 0.0% change in share price the following day. Over the last year, DXLG shares have declined by 30.31%, indicating a bearish sentiment among long-term shareholders. Investors will be closely watching for both the earnings results and the company's future guidance.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 4:01 pm

CWBHF

Charlottes Web Holdings (OTC:CWBHF) is expected to report its quarterly earnings on Thursday, 2024-03-21, with an estimated EPS of $-0.07. Historical performance shows a pattern of not meeting EPS estimates, leading to negative stock price reactions. Shares are currently trading at $0.18, down 41.22% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 4:01 pm